Biography
Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs. He helps clients develop strategies for product lifecycle management, obtaining approval, managing post-marketing issues, and defining periods of exclusivity. As the co-founder and primary author of Hyman, Phelps & McNamara’s FDA Law Blog, Mr. Karst often leads the response to new rules and regulations, sharing his interpretation with the broader legal community. Mr. Karst clerked for Hyman Phelps & McNamara while attending law school and served as articles editor for the American University Law Review. Before joining the firm, Mr. Karst lobbied for F. Hoffmann-La Roche Inc. In 1995, he was awarded a Fulbright Scholarship for post-graduate studies in Germany.
Research Interest
Pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs.
Biography
Volkmar Weissig, Sc.D., Ph.D. is a Tenured Full Professor of Pharmacology and Chair of the Department of Pharmaceutical Sciences. Dr. Weissig received his B.S., M.S. and Ph.D. degrees in Chemistry and his postdoctoral Sc.D. degree in Biochemistry and Pharmaceutical Biotechnology from the Martin-Luther University in Halle (Germany). Combined he completed several years of postdoctoral fellowships at the Cardiology Research Center in Moscow (Russia), at the Academic Department of Medicine at the Royal Free Hospital School of Medicine in London (UK), at the Institute of Organic Chemistry at the Czechoslovakian Academy of Science in Prague (CSFR), at the College of Pharmacy and the College of Medicine at the University of Florida, Gainesville, FL and at Harvard Medical School and Massachusetts General Hospital in Boston, MA. Before joining the faculty at Midwestern University, Dr. Weissig was an Assistant Professor of Pharmaceutical Sciences at Northeastern University in Boston, MA. Dr. Weissig holds 16 patents and he has published 98 research papers, review articles and book chapters, mostly in the area of nano drug delivery systems. He also edited and published 8 books. He serves as the Associate Editor of the Journal of Liposome Research and he is member of several other Editorial Boards. In July 2009 Dr. Weissig was inducted into the World Technology Network as a Fellow. In October 2014 Dr. Weissig was elected President of the World Mitochondria Society.
Research Interest
Dr. Weissig’s major research interests lie in the areas of Mitochondrial Medicine and Pharmaceutical Nanotechnology. In particular, his laboratory has pioneered the design and development of mitochondria-targeted nano drug delivery systems, which have opened new strategies for mitochondrial gene therapy, for apoptosis-based anticancer chemotherapies and for controlling and manipulating the redox status of mammalian mitochondria.
Biography
Radostina Alexandrova Graduated with honors in Biochemistry and Microbiology, Sofia University “St. Kl. Ohridski†(SU); MSc and PhD in Virology, lecturer in SU and PhD School of BAS; > 160 publications, > 550 abstracts, 3 Book chapters; Postdoctoral training in Slovakia, Hungary, Denmark; Leading researcher in 5 national and 10 bilateral projects; MC Member of five COST Actions; Member of Union of Scientists in Bulgaria, Bulgarian Society of Anatomy, Secretary-Treasurer of the Immunological Society; Member of the Organizing/Scientific Committees of 45 scientific forums; Editor/Member of editorial boards of 2 national and 4 international journals; Editor of the proceeding books of two Workshops.
Research Interest
Biochemistry and Microbiology